Latest news with #PacificBiosciences
Yahoo
6 days ago
- Business
- Yahoo
PacBio (PACB) Q2 Earnings Report Preview: What To Look For
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results this Thursday afternoon. Here's what to expect. PacBio beat analysts' revenue expectations by 5.2% last quarter, reporting revenues of $37.15 million, down 4.3% year on year. It was a stunning quarter for the company, with a solid beat of analysts' EPS estimates. Is PacBio a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting PacBio's revenue to grow 2.6% year on year to $36.96 million, a reversal from the 24.3% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.17 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. PacBio has missed Wall Street's revenue estimates four times over the last two years. Looking at PacBio's peers in the life sciences tools & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Illumina's revenues decreased 3% year on year, beating analysts' expectations by 1%, and West Pharmaceutical Services reported revenues up 9.2%, topping estimates by 5.6%. Illumina traded down 8% following the results while West Pharmaceutical Services was up 15.9%. Read our full analysis of Illumina's results here and West Pharmaceutical Services's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. PacBio is down 4.1% during the same time and is heading into earnings with an average analyst price target of $2.06 (compared to the current share price of $1.41). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
29-07-2025
- Business
- Yahoo
Pacific Biosciences (PACB) Jumps 6.5% Ahead of Earnings
We recently published . Pacific Biosciences of California, Inc. (NASDAQ:PACB) is one of the best-performing stocks on Monday. Pacific Biosciences jumped by 6.49 percent on Monday to close at $1.64 apiece as investors began repositioning portfolios ahead of its second-quarter earnings release. According to the company, it is scheduled to announce the results of its financial and operating highlights after market close on August 7, where investors will closely watch out for updates on its restructuring plan in a bid to reduce operating expenses by $45-$50 million by the end of the year. An investor call will be held on the same day to elaborate on the results. In the first quarter of the year, Pacific Biosciences of California, Inc. (NASDAQ:PACB) widened its net loss by 446 percent to $426 million from $78 million in the same period last year, following a 429-percent expansion in operating loss. Revenues amounted to $37.1 million, lower by 4.6 percent than the $38.8 million year-on-year. While we acknowledge the potential of PACB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
11-07-2025
- Business
- Yahoo
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.50, moving +1.35% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.28%. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq added 0.09%. The stock of maker of genetic analysis technology has risen by 27.59% in the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37%. The investment community will be paying close attention to the earnings performance of Pacific Biosciences of California in its upcoming release. In that report, analysts expect Pacific Biosciences of California to post earnings of -$0.18 per share. This would mark year-over-year growth of 10%. In the meantime, our current consensus estimate forecasts the revenue to be $36.46 million, indicating a 1.26% growth compared to the corresponding quarter of the prior year. For the full year, the Zacks Consensus Estimates project earnings of -$0.64 per share and a revenue of $155.12 million, demonstrating changes of +22.89% and +0.72%, respectively, from the preceding year. Investors should also take note of any recent adjustments to analyst estimates for Pacific Biosciences of California. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Pacific Biosciences of California boasts a Zacks Rank of #1 (Strong Buy). The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 173, putting it in the bottom 30% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
Why Is Steris (STE) Down 1.8% Since Last Earnings Report?
A month has gone by since the last earnings report for Steris (STE). Shares have lost about 1.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Steris due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. It turns out, estimates revision have trended downward during the past month. At this time, Steris has an average Growth Score of C, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Steris has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Steris is part of the Zacks Medical - Instruments industry. Over the past month, Pacific Biosciences of California (PACB), a stock from the same industry, has gained 11.3%. The company reported its results for the quarter ended March 2025 more than a month ago. Pacific Biosciences reported revenues of $37.15 million in the last reported quarter, representing a year-over-year change of -4.3%. EPS of -$0.15 for the same period compares with -$0.26 a year ago. Pacific Biosciences is expected to post a loss of $0.18 per share for the current quarter, representing a year-over-year change of +10%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.4%. Pacific Biosciences has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
08-05-2025
- Business
- Yahoo
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street's revenue expectations , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% above analysts' consensus estimates. Is now the time to buy PacBio? Find out in our full research report. Revenue: $37.15 million vs analyst estimates of $35.3 million (4.3% year-on-year decline, 5.2% beat) Adjusted EPS: -$0.15 vs analyst estimates of -$0.19 (20.5% beat) Operating Margin: -1,155%, down from -210% in the same quarter last year Market Capitalization: $339 million 'We are off to a solid start to the year, highlighted by a full quarter of shipments of the Vega platform, record consumables revenue and improved non-GAAP gross margin,' said Christian Henry, President and Chief Executive Officer. Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, PacBio's sales grew at a decent 11.1% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. PacBio's recent performance shows its demand has slowed as its annualized revenue growth of 6.6% over the last two years was below its five-year trend. This quarter, PacBio's revenue fell by 4.3% year on year to $37.15 million but beat Wall Street's estimates by 5.2%. Looking ahead, sell-side analysts expect revenue to grow 10.2% over the next 12 months, an improvement versus the last two years. This projection is noteworthy and implies its newer products and services will fuel better top-line performance. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. PacBio's high expenses have contributed to an average operating margin of negative 256% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, PacBio's operating margin decreased significantly over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 300 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. PacBio's operating margin was negative 1,155% this quarter. The company's consistent lack of profits raise a flag. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. PacBio's earnings losses deepened over the last five years as its EPS dropped 1.8% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, PacBio's low margin of safety could leave its stock price susceptible to large downswings. In Q1, PacBio reported EPS at negative $0.15, up from negative $0.26 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects PacBio to improve its earnings losses. Analysts forecast its full-year EPS of negative $0.70 will advance to negative $0.69. We were impressed by how significantly PacBio blew past analysts' revenue expectations this quarter. We were also glad its EPS outperformed Wall Street's estimates. Zooming out, we think this was a good print with some key areas of upside. Investors were likely hoping for more, and shares traded down 2.5% to $1.16 immediately following the results. So do we think PacBio is an attractive buy at the current price? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
